Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02597465
Recruitment Status : Withdrawn (Sponsor decided not to initiate the study for alternate commercial strategy)
First Posted : November 5, 2015
Last Update Posted : December 14, 2020
Sponsor:
Information provided by (Responsible Party):
Sun Pharma Advanced Research Company Limited

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
An open label study to determine the efficacy and safety of SPARC1507

Condition or disease Intervention/treatment Phase
Advanced Biliary Tract Cancer Drug: SPARC1507 Drug: Reference1507 Phase 3

Detailed Description:
Subjects with advanced Biliary tract carcinoma meeting the eligibility criteria will be randomized in this study.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 in Subjects With Cancer
Estimated Study Start Date : December 1, 2018
Estimated Primary Completion Date : March 1, 2019
Estimated Study Completion Date : December 1, 2019

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: SPARC1507
SPARC1507
 Drug: SPARC1507
The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle
Experimental: Chemotherapy
Chemotherapy
 Drug: Reference1507
Investigators choice including chemotherapy or supportive therapy


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Progression Free Survival (PFS) of subjects treated with SPARC1507 versus IC, per Response Evaluation Criteria in Solid Tumors version 1.1 [ Time Frame: 3 years and 6 months ]

Secondary Outcome Measures :
  1. Overall survival in subjects treated with SPARC1507 versus Investigators choice [ Time Frame: 3 years and 6 months ]
  2. Overall response rate in subjects treated with PICN versus Investigators choice [ Time Frame: 3 years and 6 months ]
  3. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 3 years and 6 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Evidence of advanced/metastatic biliary tract cancer
  • Male or female ≥ 18 years old
  • Participants must have measurable disease according to RECIST
  • ECOG performance status ≤ 1

Exclusion Criteria:

  • Known hypersensitivity to trial treatments, or their excipients
  • Prior history of treatment with any taxane therapy
  • Cardiovascular disorders as per Investigator's discretion
  • The subject has received radiation therapy
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02597465


Locations
Layout table for location information
United States, Colorado
SPARC study site
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
Sun Pharma Advanced Research Company Limited
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Sun Pharma Advanced Research Company Limited
ClinicalTrials.gov Identifier: NCT02597465    
Other Study ID Numbers: CLR_15_07
First Posted: November 5, 2015    Key Record Dates
Last Update Posted: December 14, 2020
Last Verified: December 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Biliary Tract Neoplasms
Digestive System Neoplasms
Neoplasms by Site
 Neoplasms
Biliary Tract Diseases
Digestive System Diseases